Short stature homeobox (SHOX)

Short stature homeobox (SHOX) is a critical transcription factor encoded by a gene located in the pseudoautosomal region 1 (PAR1) of the X and Y chromosomes. It plays a pivotal role in the development and maturation of the human skeleton, particularly the long bones of the arms and legs, by regulating the proliferation, differentiation, and apoptosis of chondrocytes within the growth plate. SHOX functions as a transcriptional activator, modulating the expression of downstream targets such as FGFR3 and natriuretic peptide B (NPPB). Haploinsufficiency of the SHOX gene, resulting from deletions or point mutations, is the primary cause of Léri-Weill dyschondrosteosis and a major contributor to the short stature and skeletal deformities (such as Madelung deformity) seen in Turner syndrome and idiopathic short stature. While no drugs currently bind directly to the SHOX protein, recombinant human growth hormone (Somatropin) is the standard therapeutic intervention used to promote linear growth in patients with SHOX deficiency. Clinical management focuses on early genetic screening and monitoring of growth velocity and skeletal alignment to optimize height outcomes.

Other names

SHOX HomeoboxPHOGPseudoautosomal homeobox-containing osteogenic proteinGCFXGrowth control factor X-linkedSSSHOXYSHOX1

Somatropin acts as a growth hormone receptor agonist, stimulating the production of insulin-like growth factor 1 (IGF-1) and promoting longitudinal bone growth to compensate for the growth failure caused by SHOX haploinsufficiency.